Fluconazole susceptibility testing of Candida species by flow cytometry
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Joung, Young Hee | - |
dc.contributor.author | Kim, Hye Ryoun | - |
dc.contributor.author | Lee, Mi Kyung | - |
dc.contributor.author | Park, Ae Ja | - |
dc.date.available | 2019-05-30T06:33:23Z | - |
dc.date.issued | 2007-05 | - |
dc.identifier.issn | 0163-4453 | - |
dc.identifier.issn | 1532-2742 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/24085 | - |
dc.description.abstract | Objective: Currently, antifungal drug susceptibility testing is labor-intensive, limited by delays in obtaining results and high costs. The purpose of this study was to determine the usefulness of flow cytometry (FCM) antifungal drug susceptibility testing as a routine laboratory procedure. Methods: A total of 24 clinical isolates of Candida spp. and reference strains were tested for susceptibility to fluconazole by FCM using propidium iodide (PI) as an indicator of viability. The minimum inhibitory concentration (MIC) was defined as the lowest concentration of fluconazole that resulted in an increase of 30% in mean channel fluorescence (MCF), compared to the growth control. FCM results were compared with MIC results as determined by the Clinical and Laboratory Standards Institute (CLSI) method. Results: An 8 h incubation was sufficient for determination of the MICs. The results by FCM at 8 h and the NCCLS methods at 24 h showed 87.5% agreement to within two drug dilutions. However, the FCM method is tabor-intensive in proportion to the larger number of samples. For Candida lusitaniae, MICs by the FCM method showed poor correlation with the CLSI method. Conclusions: Further evaluation is necessary to assess the usefulness of FCM as a technique for routine antifungal MIC testing in the clinical laboratory. (c) 2006 The British Infection Society. Published by Elsevier Ltd. All rights reserved. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | W B SAUNDERS CO LTD | - |
dc.title | Fluconazole susceptibility testing of Candida species by flow cytometry | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jinf.2006.09.016 | - |
dc.identifier.bibliographicCitation | JOURNAL OF INFECTION, v.54, no.5, pp 504 - 508 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000246442900015 | - |
dc.identifier.scopusid | 2-s2.0-34147155818 | - |
dc.citation.endPage | 508 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 504 | - |
dc.citation.title | JOURNAL OF INFECTION | - |
dc.citation.volume | 54 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Candida | - |
dc.subject.keywordAuthor | fluconazote | - |
dc.subject.keywordAuthor | antifungal drug susceptibility testing | - |
dc.subject.keywordAuthor | flow cytometry | - |
dc.subject.keywordAuthor | propidium iodide | - |
dc.subject.keywordPlus | CELL-CYCLE KINETICS | - |
dc.subject.keywordPlus | AMPHOTERICIN-B | - |
dc.subject.keywordPlus | ANTIBIOTIC SUSCEPTIBILITY | - |
dc.subject.keywordPlus | ESCHERICHIA-COLI | - |
dc.subject.keywordPlus | RAPID ASSESSMENT | - |
dc.subject.keywordPlus | ALBICANS | - |
dc.subject.keywordPlus | NCCLS | - |
dc.subject.keywordPlus | MICROBIOLOGY | - |
dc.subject.keywordPlus | BACTERIA | - |
dc.subject.keywordPlus | THERAPY | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.